Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cortexyme Inc (NQ: CRTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cortexyme Inc < Previous 1 2 3 4 5 Next > Cortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate July 23, 2021 Cortexyme Inc (NASDAQ: CRTX) has selected COR803 to further evaluate for coronavirus infections, including COVID-19 disease. COR803 is a novel patent-pending small... Via Benzinga Exposures COVID-19 Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection July 23, 2021 From Cortexyme, Inc. Via Business Wire The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO July 22, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs July 23, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... Via Benzinga Cortexyme to Present New Data at AAIC 2021 July 22, 2021 From Cortexyme, Inc. Via Business Wire Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 July 21, 2021 From Cortexyme, Inc. Via Business Wire Cortexyme to Host Symposium at AAIC 2021 July 19, 2021 From Cortexyme, Inc. Via Business Wire Biogen Stock Drags On Alzheimer's Players As FDA Requests Review Of Aduhelm Approval July 09, 2021 Biogen stock tumbled Friday after the FDA requested an independent review of the process that led to its recent Alzheimer's approval. Via Investor's Business Daily Exposures Product Safety Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat July 08, 2021 From Cortexyme, Inc. Via Business Wire The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs June 25, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... Via Benzinga Exposures COVID-19 Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use? June 08, 2021 Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. Via Investor's Business Daily Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab June 07, 2021 The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. Via Investor's Business Daily Exposures Product Safety Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting June 01, 2021 From Cortexyme, Inc. Via Business Wire Cortexyme to Present at Investor Conferences in June 2021 May 26, 2021 From Cortexyme, Inc. Via Business Wire The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks May 21, 2021 The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. Via Investor's Business Daily Exposures Product Safety Cortexyme Provides Business Update and Reports First Quarter 2021 Results May 10, 2021 From Cortexyme, Inc. Via Business Wire Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021 May 04, 2021 From Cortexyme, Inc. Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.